Neuromuscular Ranked: 6 Binary Catalysts From DMD to FSHD

Everyone watches oncology for the binary events. The neuromuscular field is where the binary is actually real, and the market still prices failure. Duchenne muscular dystrophy, spinal muscular atrophy, limb-girdle muscular dystrophy, and facioscapulohumeral muscular dystrophy share one thesis: a small, desperate patient population, orphan pricing power, and a 2026-to-2027 catalyst stack denser than anything else in biotech. Underneath it is a modality war most investors skip. AAV gene therapy versus antisense and exon-skipping versus antibody-oligonucleotide conjugates versus cell therapy versus small molecules. In muscle, delivery is the whole ballgame, and the winners are whoever gets the molecule into the tissue.

The patient math is why the field behaves the way it does. DMD has roughly 15,000 to 20,000 U.S. patients, SMA about 10,000 to 15,000 U.S. patients on an SMN therapy, LGMD2I/R9 a few thousand, and FSHD 45,000 to 87,000 across the U.S. and Europe. Every one of them is a six or seven-figure annual therapy when a drug works, which is why a single approval can move a mid-cap by double digits and a single miss can halve it. uniQure’s AMT-130 for Huntington’s disease is the same story one disease over, a gene therapy heading toward a regulatory filing. This roundup ranks the six names by nearest catalyst, with prices from Polygon’s August 29 close. The recurring frame is the same one the rare disease PDUFA set uses.

Scholar Rock: The Nearest Binary, $7.04 Billion

Apitegromab, the first muscle-targeted add-on for SMA, faces a September 30 PDUFA. The Phase 3 SAPPHIRE trial (NCT05156320) met its primary endpoint with a 1.8-point improvement on the Hammersmith Functional Motor Scale Expanded versus placebo (p=0.0192). Some 30.4% of apitegromab patients gained at least 3 points on the scale versus 12.5% on placebo. But the 20 mg/kg dose, the one Scholar Rock would commercialize, missed on its own (p=0.1149), while the 10 mg/kg dose carried the trial with a 2.2-point benefit (p=0.0121). An FDA reviewer will notice. Add the Catalent manufacturing overhang, and this is not the lock the $7.04 billion market cap implies. The full apitegromab SMA PDUFA primer. The comp that matters: Scholar Rock is worth 3.2x what the market pays Sarepta, a company with $2.2 billion in actual muscle-disease revenue. Approve it, and the stock re-rates toward $9 to $10 billion; a restricted label sends it down 30%.

Capricor: The Highest-Risk Turnaround, $590 Million

Deramiocel, an allogeneic cell therapy for DMD, is the field’s most speculative name. The FDA’s advisory committee voted 9 to 3 against approval in July, and Capricor retreated to an upper-limb-only claim, which pushed the PDUFA to November 22. The prespecified PUL 2.0 analysis showed a 0.66-point difference with a p-value of 0.24, which is why the panel balked. STAT has reported the FDA is heading for rejection. At a $590 million market cap, the market is pricing a low-probability longshot, and that is roughly what it is. The deramiocel AdComm vote and the amendment reset tell the full story. This is a binary where the downside is another rejection, not a valuation debate.

BridgeBio: The Cleanest Data, Priced In, $15 Billion

BBP-418 (povelvertide) has the cleanest registrational package in the field. In the Phase 3 FORTIFY trial (NCT04202627), LGMD2I patients on BBP-418 gained 0.27 meters per second on the 100-meter timed test versus placebo (p<0.0001), forced vital capacity rose 5% (p=0.0071), and creatine kinase dropped 82%. The FDA skipped the advisory committee, and a November 27 PDUFA plus a Priority Review Voucher worth over $100 million awaits. The problem is the price: at $76.60, BridgeBio is worth about $15 billion, and the BBP-418 PDUFA analysis is already in the stock. Compare it to Sarepta, worth $2.2 billion with $2.2 billion in revenue. BridgeBio is the growth story, not the value story.

Dyne: The Platform Story, $4.1 Billion

Dyne’s z-rostudirsen is the threat to Sarepta’s exon-skipping franchise. The BLA was accepted with Priority Review, with a January 21, 2027 PDUFA. In the DELIVER trial, z-rostudirsen produced 5.46% muscle-adjusted dystrophin versus 0.3% for Sarepta’s Exondys 51, a roughly 10-fold improvement, and it doses monthly instead of weekly. The full case is that the FORCE platform changes the delivery math in DMD. The risk is the accelerated-approval pathway: dystrophin is a surrogate, and the confirmatory FORZETTO Phase 3, roughly 90 ambulatory boys measuring rise-from-floor velocity at week 73, will not read out for 18-plus months. At $4.1 billion with zero approved products, Dyne is priced for a win it has not banked yet, though analysts average $34 to $40, implying 45% to 70% upside.

Sarepta: The Contrarian Value, $2.2 Billion

Sarepta is the field’s cautionary tale and, oddly, its cheapest name. Elevidys, the $3.2 million DMD gene therapy, went from $898.7 million in 2025 revenue to roughly $100 million a quarter after the liver-failure safety signal. The stock fell from $178 to a $15.68 low. But the numbers now argue the market has over-corrected: $945 million in cash, four approved drugs, $1.2 to $1.3 billion in 2026 guidance, and a market cap of $2.2 billion. The PMO franchise, Exondys 51, Vyondys 53, and Amondys 45, still generates about $230 million a quarter, which nearly covers the market cap on its own. That is roughly 1x forward revenue against BioMarin’s 4x for a comparable rare disease portfolio. The full contrarian case on the Elevidys DMD franchise. The binary is the February 28, 2027 decision on whether the FDA converts two failed PMO drugs to full approval on real-world evidence. If it goes Sarepta’s way, the stock re-rates toward $29 to $35.

Novartis: The Mega-Cap You Cannot Trade, $292 Billion

The FSHD story is real but it is not a Novartis trade. Del-brax, the antibody-oligonucleotide conjugate Novartis got in the $12 billion Avidity acquisition, hit its biomarker endpoints in the FORTITUDE trial and is filing a BLA under accelerated approval in H2 2026. FSHD has zero approved treatments and 45,000 to 87,000 patients. But del-brax peak sales of $1 to $2 billion are about 3% of Novartis revenue. The full analysis reaches the same conclusion: the approval is likely, the stock will not move. Watch Arrowhead’s ARO-DUX4 as the next tradable FSHD catalyst.

The Risk

DMD is the graveyard of gene-therapy expectations, and the FDA’s stance on surrogate endpoints is tightening. Elevidys was approved on a biomarker and later drew scrutiny; Dyne’s z-rostudirsen is filing on the same kind of surrogate. The through-line risk across all six names is the one the surrogate endpoint explainer walks through: a biomarker win does not guarantee a functional win, and the confirmatory trial is where these stories either hold or break. In muscle, that gap is wider than anywhere else in biotech, because the functional endpoints, walking speed, breathing, rising from the floor, take years to move even when the biology is working.

The Verdict

Ranked by risk-reward:

1. Scholar Rock is the nearest binary and the only one inside 30 days, but at $7.04 billion it is priced for the win. Size it small.
2. Dyne is the platform bet with the January 2027 catalyst, and the 10x dystrophin data is a moat no competing platform shows.
3. Sarepta is the contrarian value: 1x revenue, four drugs, $945 million in cash, and two binary events that could re-rate it 40% to 65%.
4. BridgeBio is the growth story with the cleanest data, but it is already priced in at $15 billion.
5. Novartis is a hold; the FSHD approval is real but immaterial.
6. Capricor is the longshot. The AdCom already said no, and the upper-limb pivot is a Hail Mary.

The common thread is that delivery is destiny in muscle. The companies that solved the delivery problem, Dyne’s antibody conjugate and Novartis’s AOC, are the ones with durable advantages. The ones still fighting on a surrogate endpoint are the ones that will keep investors up at night.